Celgene International Sárl Release: Preliminary Results from International Study Report That REVLIMID(R) Provides Responses for Patients with Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma

COPENHAGEN, Denmark--(BUSINESS WIRE)--Celgene International Sárl (Nasdaq:CELG) today announced that preliminary data from an international study of single agent REVLIMID (lenalidomide) in relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL) were presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark.